Fingolimod Capsules (Gilenya)

Elliot, William T.; Chan, James
November 2010
Internal Medicine Alert;11/15/2010, Vol. 32 Issue 21, p165
The article focuses on the therapeutic use of fingolimod for patients with multiple sclerosis.


Related Articles

  • Sphingosine 1-Phosphate Receptor 1 as a Useful Target for Treatment of Multiple Sclerosis. Chiba, Kenji; Adachi, Kunitomo // Pharmaceuticals;May2012, Vol. 5 Issue 5, p514 

    Sphingosine 1-phosphate (S1P), a lysophospholipid mediator, is generated from sphingosine by sphingosine kinases and binds five known cell surface receptors. S1P receptor 1 (S1P1) plays an essential role in lymphocyte egress from secondary lymphoid organs (SLO), as evinced by the inability of...

  • The dual S1PR1/S1PR5 drug BAF312 (Siponimod) attenuates demyelination in organotypic slice cultures. O'Sullivan, Catherine; Schubart, Anna; Mir, Anis K.; Dev, Kumlesh K. // Journal of Neuroinflammation;2/8/2016, Vol. 13, p1 

    Background: BAF312 (Siponimod) is a dual agonist at the sphingosine-1 phosphate receptors, S1PR1 and S1PR5. This drug is currently undergoing clinical trials for the treatment of secondary progressive multiple sclerosis (MS). Here, we investigated the effects of BAF312 on isolated...

  • S1P Receptor Modulators in Cell Trafficking and Therapeutics. Gonzalez-Cabrera, Pedro J.; Cahalan, Stuart M.; Ferguson, Jill; Rosen, Hugh // Current Immunology Reviews;May2012, Vol. 8 Issue 2, p170 

    FTY720 (fingolimod, Gilenya ) is a sphingosine analog prodrug that induces lymphocyte sequestration in secondary lymphoid organs, resulting in peripheral lymphopenia. Lymphopenia by FTY720 is characterized by a dose-dependent and sustained reduction of circulating T and B lymphocytes within...

  • FTY720 on the way from the base camp to the summit of the mountain: relevance for remyelination. Kipp, M; Amor, S // Multiple Sclerosis Journal;Mar2012, Vol. 18 Issue 3, p258 

    FTY720 (fingolimod; Gilenya�), a sphingosine 1-phosphate (S1P) receptor modulator, is the first oral disease-modifying therapy to be approved for the treatment of relapsing�remitting multiple sclerosis. FTY720 is rapidly converted in vivo to the active S-fingolimod-phosphate, which...

  • Solid interim data drive Receptos MS drug into Phase III. Powers, Marie // BioWorld Today;12/6/2013, Vol. 24 Issue 234, p1 

    The article reports that positive data from Phase II portion of RADIANCE has moved biopharmaceutical company Receptos Inc. nearer its goal of setting a safe standard for the oral therapy RPC1063 in the treatment of relapsing multiple sclerosis. It offers information on the interim findings of...

  • FTY720 (Fingolimod) Provides Insight into the Molecular Mechanisms of Multiple Sclerosis. CRAWFORD, MADELYN // Pursuit: The Journal of Undergraduate Research at the University;2014, Vol. 5 Issue 1, p27 

    Multiple sclerosis (MS) is a neurodegenerative disorder caused by a prolonged immunemediated inflammatory response that targets myelin. Nearly all of the drugs approved for the treatment of MS are general immunosuppressants or only function in symptom management. The oral medication fingolimod,...

  • Actions of a picomolar short-acting S1P1 agonist in S1P1-eGFP knock-in mice. Cahalan, Stuart M.; Gonzalez-Cabrera, Pedro J.; Sarkisyan, Gor; Nguyen, Nhan; Schaeffer, Marie-Therese; Huang, Liming; Yeager, Adam; Clemons, Bryan; Scott, Fiona; Rosen, Hugh // Nature Chemical Biology;May2011, Vol. 7 Issue 5, p254 

    Sphingosine 1-phosphate receptor 1 (S1P1) is critical for lymphocyte recirculation and is a clinical target for treatment of multiple sclerosis. By generating a short-duration S1P1 agonist and mice in which fluorescently tagged S1P1 replaces wild-type receptor, we elucidate physiological and...

  • Infections cast cloud over Novartis' MS therapy. Garber, Ken // Nature Biotechnology;Aug2008, Vol. 26 Issue 8, p844 

    This article discusses the possibility that infections will undermine phase three tests of the small molecule FTY720 (fingolimod) developed by Novartis AG for the treatment of multiple sclerosis (MS). This drug, an immunosuppressant, binds to sphingosine-1 phosphate (S1P) receptors. This...

  • MS Drug's Therapeutic, Adverse Effects Separated in New Study. Breindl, Anette // BioWorld Today;5/11/2011, Vol. 22 Issue 91, p1 

    The article focuses on the possible adverse effects of Gilenya (fingolimod), an oral drug for multiple sclerosis, and the suggested ways on how to improve its safety profile. It provides an overview of the study conducted by Timothy Hla and his colleagues at Weill Cornell Medical College...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics